Woburn, MA Azurity Pharmaceuticals moved its national headquarters to a 14,627 s/f space at 8 Cabot Rd., a Cummings Properties building in a growing biotech community.
The pharmaceutical company had outgrown its previous location, on Presidential Way in town, and is expanding its manufacturing site in Wilmington. It also has campuses in the greater Denver and Kansas City areas.
Cummings Properties key accounts manager Marc Knittle worked on the lease with Ron Scarboro, chief operational and financial officer at Azurity Pharmaceuticals, and John Carroll, executive vice president at Colliers International’s Boston office.
“We are delighted that Azurity is expanding its presence in Woburn’s biotech cluster,” said Knittle. “More and more companies are finding that, compared with Boston and Cambridge, the northern suburbs offer much lower rates and less traffic, creating an ideal environment in which to grow their businesses.”
Among Azurity’s new neighbors are life sciences firms Amgen, Covaris, Bio2 Technologies, Laurus Synthesis, and Modular Genetics.
Located at the intersection of I-93 and I-95, 8 Cabot Rd. is a modern glass-and-brick building that was designed and built by Cummings Properties’ in house architects and construction teams. Supported by solar power and designed to meet LEED certification standards, it offers energy-efficient space suitable for both office and R&D applications.
Azurity was formed by CutisPharma, Inc.’s May acquisition of Silvergate Pharmaceuticals, Inc.
The privately held firm develops and manufactures customized drug formulations for patients who are unable to swallow tablets and capsules and whose needs are not served by other commercially available therapies.
Azurity’s new facility is also within walking distance of Woburn Mall, which is currently being redeveloped into Woburn Village, a mixed-use site with an outdoor market feel that is expected to be similar to the 3rd Avenue complex in Burlington and MarketStreet in Lynnfield.